RLMD Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
15.0M
-22.9%
19.5M
-4.3%
20.3M
+96.9%
10.3M
+1.0%
10.2M
R&D
8.4M
+3.8%
8.1M
+0.2%
8.1M
+100.0%
4.0M
+43.2%
2.8M
SG&A
6.6M
-41.8%
11.4M
-7.2%
12.3M
+94.9%
6.3M
-15.0%
7.4M
Operating Income
-15011027
+22.9%
-19461754
+4.3%
-20333112
-96.9%
-10327346
-1.0%
-10221306
EBITDA
-15011027
+22.9%
-19461754
+4.3%
-20333112
-96.9%
-10327346
-1.0%
-10221306
Net Income
-12914185
+32.2%
-19051956
+4.1%
-19867760
-96.9%
-10091496
-2.3%
-9866442
EPS (Basic)
$-0.11
+50.0%
$-0.22
+33.3%
$-0.33
-10.0%
$-0.30
+0.0%
$-0.30
EPS (Diluted)
$-0.11
+50.0%
$-0.22
+33.3%
$-0.33
-10.0%
$-0.30
+0.0%
$-0.30
Shares (Diluted)
112.4M
+29.8%
86.6M
+41.7%
61.1M
+84.2%
33.2M
+0.0%
33.2M
Relmada Therapeutics (RLMD) โ€” Financials